Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;42(4):387-97.
doi: 10.1016/j.npep.2008.04.009. Epub 2008 Jun 12.

Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests

Xiaoying Lu  1 , Brendon Ross, Manuel Sanchez-Alavez, Eric P Zorrilla, Tamas Bartfai
Affiliations

Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests

Xiaoying Lu et al. Neuropeptides. 2008 Aug.

Abstract

Neuropeptide galanin modulates a variety of central nervous system functions by signaling through three G-protein-coupled receptor subtypes, GalR1 through GalR3. Galanin and its receptors are expressed at high levels in the limbic structures of the rodent brain. Intracerebroventricular injection of galanin has been shown to modulate depression and anxiety-like behaviors in the rat. We have previously shown that chronic antidepressant treatments increase the binding of a GalR2-preferring ligand, galanin (2-11), to the dorsal raphe nucleus (DRN) of the rat, which, along with the finding that intra-DRN infusion of galanin (2-11) increases the release of serotonin in the hippocampus, suggests that GalR2 signaling might exert antidepressant-like actions by modulating ascending serotonergic outflow. Recently, two research groups reported their phenotypic analysis of a GalR2 knockout (GalR2KO) mouse line, produced by gene-trapping method and maintained on a 129S1/SvImJ genetic background. The only positive finding in that GalR2KO mouse line was an anxiogenic-like phenotype specific to the elevated plus-maze. Because it is known that genetic background can affect the outcome of behavioral tests, in the present study, we analyzed a separate GalR2KO line, which was produced by targeted deletion and maintained on a C57BL/6 background, using a different set of depression- and anxiety-related tests. GalR2KO mice exhibited a more persistent depressive-like phenotype in the learned helplessness paradigm as well as increased immobility in the tail suspension test when results from the present studies were combined by fixed effect meta-analysis with that reported by Gottsch and colleagues. GalR2KO mutants showed anxiety-like behavior comparable to wild-type littermates in the elevated plus-maze, open-field, and light-dark transfer tests. The present findings are consistent with a predicted antidepressant-like effect of GalR2 signaling, suggesting that GalR2 might be a valid drug target for depressive disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Light dark transfer. There was no significant difference between the wild type and GalR2KO in the time spent in the light compartment or the total number of transitions in the light dark transfer test (n=16 wild type, 16 GalR2KO). All bars represent mean values with vertical lines indicating 1 SEM.
Figure 2
Figure 2
Tail suspension (A) and forced swim test (B). There was no significant difference between the wild type and GalR2KO in immobility in the tail suspension test (left) and in the forced swim test (right) (n=15 wild type, 14 GalR2KO). All bars represent mean values with vertical lines indicating 1 SEM.
Figure 3
Figure 3
Open field test. There was no significant difference between the wild type and GalR2KO in general locomoter activity as measured by total line crossings or in center time (n=16 wild type, 16 GalR2KO). All bars represent mean values with vertical lines indicating 1 SEM.
Figure 4
Figure 4
The learned helplessness data were analyzed in 3 blocks that consisted of 10 to 11 trials each. All bars represent mean values with vertical lines indicating 1 SEM. There were significant Trial Block [within-subject] x Genotype [between-subject] interactions for % escape failure [F(2, 60)=5.89, p=0.004] and for % escape [F(2,60)=5.0, p=0.01]. There was significant differences between genotypes in percent escape failures and percent escapes in the last 10 trial block (n=16 wild type, 16 GalR2KO) and significant differences in wild type mice between the last 10 trial block and first 11 trial block in percent escape failures and percent escapes. *, p<0.05, &&, p<0.01, Bonferroni t test.
Figure 5
Figure 5
Effect of desipramine treatment on active behaviors in the forced swim test. There was a significant main effect of drug treatment [F(1,27)=14.87, P=0.0006], but not genotype, and no significant drug treatment x genotype interaction, on immobility. Likewise, there was a main effect of drug treatment on swimming F(1,27)=5.9, p=0.023] and climbing behaviors [F(1,27)=11.7, p=0.002], but no significant effect of genotype or significant drug treatment × genotype interaction was observed in these two behaviors. All bars represent mean values with vertical lines indicating 1 SEM. *, p<0.05; **, p<0.01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anseloni VZ, Motta V, Lima G, Brandao ML. Behavioral and pharmacological validation of the elevated plus maze constructed with transparent walls. Braz J Med Biol Res. 1995;28:597–601. - PubMed
    1. Bailey KR, Pavlova MN, Rohde AD, Hohmann JG, Crawley JN. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol Biochem Behav. 2007;86:8–20. - PMC - PubMed
    1. Barrera G, Echevarria DJ, Poulin JF, Laforest S, Drolet G, Morilak DA. One for all or one for one: does co-transmission unify the concept of a brain galanin “system” or clarify any consistent role in anxiety? Neuropeptides. 2005;39:289–292. - PubMed
    1. Bartfai T, Fisone G, Langel U. Galanin and galanin antagonists: molecular and biochemical perspectives. Trends Pharmacol Sci. 1992;13:312–317. - PubMed
    1. Bartfai T, Lu X, Badie-Mahdavi H, Barr AM, Mazarati A, Hua XY, Yaksh T, Haberhauer G, Ceide SC, Trembleau L, Somogyi L, Krock L, Rebek J., Jr Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci U S A. 2004;101:10470–10475. - PMC - PubMed

Publication types

Substances